Outperforming ETF manager names a potential '50-bagger' in the stock market
Sarepta Therapeutics Inc SRPT
News
-
Outperforming ETF manager names a potential -2-
Outperforming ETF manager names a potential '50-bagger' in the stock market
Outperforming ETF manager names a potential -2-
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics to Present at Upcoming Investor Conferences
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results
Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication
Sarepta Therapeutics Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
Dyne Therapeutics stock gains, Sarepta falls after muscular dystrophy trial results
Sarepta Therapeutics shares plunge as gene therapy trial falls short of primary goal
Sarepta Therapeutics to Request Expansion of Elevidys to All Age Groups Following Study Results
Sarepta Therapeutics completes sale of priority review voucher for $102 million
Sarepta Therapeutics downgraded at Evercore ISI after FDA approval of gene therapy
Sarepta Gets FDA Approval of Treatment for Duchenne Muscular Dystrophy
Sarepta gets FDA approval for rare genetic disorder treatment
Sarepta says FDA is working toward accelerated approval of its latest treatment for Duchenne muscular dystrophy